{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:35:38Z","timestamp":1764729338781,"version":"3.46.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We report the case of a 51-year-old male patient initially diagnosed with JAK2-V617F-mutated polycythemia vera (PV), who developed chronic phase BCR::ABL1-positive chronic myeloid leukemia (CML) 11 years later. The patient was treated with hydroxyurea and later with ruxolitinib (RUX) for PV. Following CML diagnosis, treatment with imatinib combined with RUX was initiated. Imatinib and RUX combination therapy proved to be safe and well-tolerated without major adverse events. After over one year of treatment, the patient maintained a complete cytogenetic response and a MR\n                    <jats:sup>2<\/jats:sup>\n                    molecular response. Imatinib was switched to dasatinib due to the unsatisfying molecular response achieved. This case highlights the uncommon coexistence of JAK2 mutation and BCR::ABL1 translocation and supports the feasibility and safety of combining JAK2 inhibitors and tyrosine kinase inhibitors in such scenarios.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06700-8","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T07:51:46Z","timestamp":1761378706000},"page":"6065-6069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy"],"prefix":"10.1007","volume":"104","author":[{"given":"Paride","family":"Bartolucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Gigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Tabanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Valeriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Gregato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"6700_CR1","unstructured":"Campo E (2008) WHO classification of tumours of Haematopoietic and lymphoid tissues. In: Swerdlow Steven H (ed) vol vol 2. International agency for research on cancer, Lyon, France"},{"issue":"17","key":"6700_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779\u20131790","journal-title":"N Engl J Med"},{"issue":"5","key":"6700_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356(5):459\u2013468","journal-title":"N Engl J Med"},{"key":"6700_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Cou\u00e9dic JPL et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia Vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"issue":"10","key":"6700_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.77","volume":"5","author":"A Zhou","year":"2015","unstructured":"Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST (2015) Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J 5(10):e351","journal-title":"Blood Cancer J"},{"issue":"8","key":"6700_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/sj.leu.2404730","volume":"21","author":"M Bornh\u00e4user","year":"2007","unstructured":"Bornh\u00e4user M (2007) Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 21(8):1824\u20131826","journal-title":"Leukemia"},{"issue":"21","key":"6700_CR7","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1200\/JCO.2012.47.8669","volume":"32","author":"O Yamada","year":"2014","unstructured":"Yamada O, Mahfoudhi E, Plo I, Ozaki K, Nakatake M, Akiyama M, Yamada H, Kawauchi K, Vainchenker W (2014) Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone. J Clin Oncol 32(21):e76\u2013e79","journal-title":"J Clin Oncol"},{"issue":"10","key":"6700_CR8","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.leukres.2008.03.004","volume":"32","author":"L Jallades","year":"2008","unstructured":"Jallades L (2008) Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 32(10):1608\u20131610","journal-title":"Leuk Res"},{"issue":"Supplement 1","key":"6700_CR9","doi-asserted-by":"publisher","first-page":"12295","DOI":"10.1182\/blood-2022-170986","volume":"140","author":"C Kevin","year":"2022","unstructured":"Kevin C, Miller JL, Story J, Foster JA, Moran AT, Fathi, Gabriela S (2022) Hobbs; emergence of chronic myeloid leukemia in patients with myeloproliferative neoplasms: A Single-Institution experience. Blood 140(Supplement 1):12295\u201312296","journal-title":"Blood"},{"issue":"6","key":"6700_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/ajh.24728","volume":"92","author":"M Kandarpa","year":"2017","unstructured":"Kandarpa M, Wu YM, Robinson D, Burke PW, Chinnaiyan AM, Talpaz M (2017) Clinical characteristics and whole exome\/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. Am J Hematol 92(6):555\u2013561","journal-title":"Am J Hematol"},{"issue":"6","key":"6700_CR11","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3324\/haematol.2013.102525","volume":"99","author":"U Alessandra Iurlo","year":"2014","unstructured":"Alessandra Iurlo U, Gianelli D, Rapezzi D, Cattaneo E, Fermo F, Binda E, Santambrogio (2014) Cristina Bucelli, Agostino Cortelezzi. Imatinib and RUX association: first experience in two patients. Haematologica 99(6):e76\u2013e77","journal-title":"Haematologica"},{"issue":"4","key":"6700_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sau\u00dfele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984","journal-title":"Leukemia"},{"issue":"12","key":"6700_CR13","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","volume":"4","author":"C Vener","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F, Ferrero A, Saglio G, Pravettoni G (2020) First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv 4(12):2723\u20132735","journal-title":"Blood Adv"},{"key":"6700_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2018.08.016","volume":"104","author":"MM Fachi","year":"2018","unstructured":"Fachi MM, Tonin FS, Leonart LP, Aguiar KS, Lenzi L, Figueiredo BC, Fernandez-Llimos F, Pontarolo R (2018) Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: a systematic review and network meta-analysis. Eur J Cancer 104:9\u201320","journal-title":"Eur J Cancer"},{"issue":"11","key":"6700_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/17425255.2023.2277758","volume":"19","author":"Sarah Allegra","year":"2023","unstructured":"Allegra Sarah, Dondi Emma, De Francia Silvia (2023) Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics. Expert Opin Drug Metab Toxicol 19(11):733\u2013739","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"6700_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"6700_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","volume":"62","author":"TYJ Appeldoorn","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ (2023) Pharmacokinetics and pharmacodynamics of RUX: A review. Clin Pharmacokinet 62(4):559\u2013571","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"6700_CR18","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","volume":"165","author":"AM Filppula","year":"2012","unstructured":"Filppula AM, Laitila J, Neuvonen PJ, Backman JT (2012) Potent mechanism-based inhibition of CYP3A4 by Imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165(8):2787\u20132798","journal-title":"Br J Pharmacol"},{"key":"6700_CR19","unstructured":"Sweet K, Othus M, Tantravahi S (2024) A phase 2, randomized trial of ruxolitinib in addition to BCR:: ABL1 TKIS in Cml patients with molecular evidence of disease (SWOG trial S1712). EHA : S174"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06700-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06700-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06700-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:10Z","timestamp":1764729070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06700-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6700"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06700-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.D. reports research funding from ADC Therapeutics, Incyte, Takeda; participation in a speaker bureau for Incyte, Roche, AbbVie, Astra Zeneca; has provided consultancy for Regeneron and served on an advisory board for Gilead, Roche, AbbVie, Sobi, Lilly, AstraZeneca.F.B. reports advisory board honorarium from Pfizer and research grant from Menarini.The other authors and co-authors (P.B., F.G., V.T., A.V., G.G., C.P.) have no relevant financial and non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}